Personalized blood disorder treatment shows promise in major trial
NCT ID NCT05438875
Summary
This study tested if adding a drug called ATRA to standard treatment (eltrombopag) works better for adults with a specific blood disorder (ITP) where steroids have failed. Researchers first tested patients' blood with a new marker to see if they might respond better to the combo. The main goal was to see if this personalized, two-drug approach could safely keep platelet counts at a safe level for 18 months without needing rescue medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PURPURA, THROMBOCYTOPENIC, IDIOPATHIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tongren hospital
Beijing, Beijing Municipality, China
-
Department of Hematology, Beijing Friendship Hospital, Capital Medical University
Beijing, China
-
Department of Hematology, Beijing Hospital
Beijing, China
-
Department of Hematology, Senior Department of Hematology, the Fifth Medical Center of PLA General Hospital
Beijing, China
-
Peking University Insititute of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality, 100010, China
Conditions
Explore the condition pages connected to this study.